At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 9, 2026 at 07:39 ET
ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus revenue estimates of $59.2M. The company also announced FDA label expansion for ANKTIVA in BCG-unresponsive NMIBC and positive Phase 2/3 data, while GAAP net loss widened to $184.6M driven by non-cash fair value changes. Cash and marketable securities stood at $334.3M.
- Q3 2026 net product revenue $48.7M, up 53% YoY from $31.8M
- First nine months 2026 net product revenue $143.6M, up 92% YoY
- Revenue miss: actual $48.7M vs consensus $59.2M
- FDA expanded ANKTIVA label on Oct 14, 2026 to include papillary-only NMIBC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access